This #WorldGODay and every day, we remain committed to driving research and innovation to improve outcomes for people with endometrial cancer. Our work to advance treatment options for #endometrialcancer is inspired by people like Alex. We're committed to elevating the voices of endometrial cancer survivors, like Alex, who help identify the unmet needs among patients that we work to address. Listen to the full conversation with GSK’s Global Medical Director in Oncology, Odette Allonby: https://gsk.me/4gze9Qn
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Brentford, Middlesex
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
Our rapidly changing environment – droughts and floods, deforestation, wildfires and rising temperatures – poses an urgent threat to human health. This also puts increasing pressure on healthcare systems, which already account for nearly 5% of global emissions. To help reduce the environmental footprint of healthcare systems, we need to ensure the development and uptake of more sustainable medicines and vaccines. Collaboration across healthcare systems, involving industry, regulators, healthcare professionals, and patients, is crucial in achieving this goal. By working together, we can deliver our ambitious company targets on climate and nature and create healthcare that is better for patients and the planet. Stay tuned for more updates during #ClimateWeekNYC and find out more: https://gsk.to/3BddZ0G
-
We understand the impact that Neglected Tropical Diseases (NTDs) have on people’s lives – from physical pain and disability to mental health issues due to stigma and isolation. Lymphatic filariasis (LF) is one NTD that causes pain and disfigurement, making everyday life a challenge. However, there is hope. Thanks to the global effort to prevent LF, we’re on the way to helping eliminate this disease worldwide. We’ve been donating medicines to help eliminate LF and treat soil transmitted helminths (STH) since 2000 and we’re celebrating with Uniting to Combat Neglected Tropical Diseases and the global NTD community, the news that 12bn tablets have been donated. Each tablet will help improve the lives of millions of people at risk of these NTDs in endemic countries. This achievement is a true reflection of the power of partnerships, and the dedication of healthcare workers in enabling access to prevention programmes. Hear direct from patients, carers and healthcare workers in Zanzibar about the impact of NTDs on their lives, and their hopes for future: https://gsk.to/3XFfaOe Unite. Act. Eliminate. It’s time to end NTDs. #BeatNTDs #ChangeTheTrajectory #UNGA79
-
🗓️Le CNIT La Défense ouvre ses portes pour accueillir le Congrès 2024 de la @Société Française d'Oto-rhino-laryngologie (ORL) - SFORL ! Venez rencontrer notre équipe, qui vous accueillera sur son stand du 20 au 22 septembre 2024 ! Au programme ? Découverte des dernières actualités dans le domaine de la Polypose Naso Sinusienne et des #Biothérapies. Nous vous attendons nombreux ! ✨ #SFORL #PNS #ORL
-
GSK is fully committed to getting ahead of antimicrobial resistance (AMR), one of the most significant health challenges the world faces. That’s why we’re working together with partners across innovation, access and antimicrobial stewardship. We’re thrilled to announce that our Worthing manufacturing facility has become the first in the UK to achieve BSI Kitemark Certification for Minimized Risk of Antimicrobial Resistance. Achieving this rigorous international certification demonstrates our commitment to the responsible manufacturing of antibiotics and our ambition is to have all global antibiotic manufacturing sites certified by the end of 2026. Learn more: https://gsk.to/3Bc71cs #UNGA79
-
Antimicrobial Resistance is a global challenge, with lower-income countries, particularly in Africa and Asia, shouldering a disproportionate burden. That's why we’re investing in Global Antibiotic R&D Partnership (GARDP) to ensure equitable access to antibiotics in these countries. We’ve committed €4.5m over three years, to collaborate in driving innovation and breaking down the barriers that prevent vital antibiotics from reaching those in need. Together, we're dedicated to making a positive impact on public health and improving lives worldwide. #PowerOf Antibiotics #ChangeTheTrajectory #UNGA79
-
Good health is our most precious asset. When people are well, they can learn, thrive, and contribute to their communities, no matter where they are in the world. Check out Emma's blog from her recent trip to Kenya where she saw first-hand the work we’re doing together to advance equitable responsible access to preventative interventions.
Since becoming CEO of GSK, I’ve kept a diary. Some entries are brief, some lengthy, and most barely legible but they often remind me of the inspiring work we do every single day to get ahead of disease. Hopefully from these videos of my recent visit to Nairobi and Siaya, you can see for yourself the positive impact we have by working together - uniting science, tech and most of all outstanding people to tackle the toughest challenges in healthcare. #AheadTogether
-
To solve the biggest health challenges, we must unite science, technology and talent. That’s why we invest in developing the next generation of diverse innovators. Through initiatives that offer mentoring support and hands-on science learning we provide opportunities and nurture early enthusiasm for science, technology, engineering and mathematics. Learn more: https://gsk.to/STEM Hear from Niramay, Amelia and Micaela about their passion for #STEM and ambitions for the future. 👇
-
#News for #Investors and #Media: Today, we announced that Japan’s Ministry of Health, Labour, and Welfare (MHLW) has accepted our application for one of our #bloodcancer therapies in combination with standards of care. Learn more: https://gsk.to/3B8kMJ0
-
At #ESMO24, we are showcasing the latest data from our oncology portfolio and raising awareness of the challenges and unmet needs for patients living with gynecologic cancers like ovarian cancer. Most people with ovarian cancer are diagnosed at an advanced stage – knowing the signs, symptoms and risk factors of ovarian cancer can help those who may be affected seek care sooner. Test your knowledge below.
This content isn’t available here
Access this content and more in the LinkedIn app